Lv1
30 积分 2025-08-13 加入
Complement factor D is a drug target for metabolic-associated fatty liver disease
14小时前
待确认
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
1天前
已完结
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
1天前
已完结
The complement system: Biology, pathology, and therapeutic interventions
4天前
已完结
Age-related macular degeneration
4天前
求助中
Therapeutic targeting of neuroimmune mechanisms in neurodegeneration
15天前
已完结
Correlations of the Complement Proteins MASP‐2 and MASP‐3 With Clinical Severity and Short‐Term Outcomes in Primary Membranous Nephropathy Patients
24天前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
1个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Indirect Effect Model with Surge-Function for Describing Melatonin Circadian Rhythm: Quantitative Comparison and Application Between Normal Sleepers and Patients with Delayed Sleep-Wake Phase Disorder
皖公网安备34019202002308
